Work

Drug development of vamorolone for Duchenne muscular dystrophy

Year: 2017

Type: article

Source: Neuromuscular Disorders

DOI: 10.1016/j.nmd.2017.06.444

Authors: P. Clemens, M. Guglieri, L. Morgenroth, J. Damsker, A. Smith, Y. Hathout, A. Cnaan, E. Smith, J. Mah, B. Byrne, D. Castro, R. Finkel, N. Kuntz, C. McDonald, Y. Nevo, M. Ryan, M. Tulinius, R. Webster, E. Hoffman

Institutions: University of Pittsburgh, Newcastle University, ReveraGen BioPharma (United States), Binghamton University, Duke University, Alberta Children's Hospital, University of Florida, The University of Texas Southwestern Medical Center, Lurie Children's Hospital, University of California, Davis, Tel Aviv University, The University of Melbourne, University of Gothenburg, Children's Hospital at Westmead

Language: English

Topic: Muscle Physiology and Disorders

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2756100490

FWCI:

Cites:

Cited by:

Related to: 10